Drugs / TEBOFORTAN
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT05594355 | Apr 2021 → Dec 2023 | cognitive disorder | Fundació ACE Institut Català de Neurociències Aplicades | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TEBOFORTAN | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05594355 ↗ |
| Route | Oral | “patients will receive 1 daily tablet of EGb 761 240 mg orally” PMID 37012306 ↗ Apr 2023 |